Journal
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY
Volume 62, Issue 3, Pages 154-157Publisher
JAPANESE SOC LYMPHORETICULAR TISSUE RESEARCH
DOI: 10.3960/jslrt.21035
Keywords
vanishing bile duct syndrome; Hodgkin lymphoma; brentuximab vedotin; liver failure
Categories
Ask authors/readers for more resources
Vanishing bile duct syndrome (VBDS) is a rare hepatic disorder with no specific treatment. We treated a patient with classic Hodgkin lymphoma (HL) and VBDS using brentuximab vedotin (BV), achieving a partial metabolic response. Our experience suggests BV could be a treatment option for classic HL with VBDS.
Vanishing bile duct syndrome (VBDS) is a rare hepatic disorder which leads to liver failure as a result of progressive destruction of the intrahepatic bile ducts. There are no treatment modalities for VBDS itself and severe hepatic dysfunction restricts the treatment of underlying diseases. We safely treated a case of classic Hodgkin lymphoma (HL) with VBDS using brentuximab vedotin (BV). The patient was treated with 5 cycles of reduced BV and a partial metabolic response was obtained. Moreover, a standard dose of BV for another 5 cycles was accomplished with minimal adverse events. Our experience indicates that BV could be a treatment option for classic HL with VBDS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available